Skip to content
HowShorted

Sonnet BioTherapeutics Holdings, Inc. short interest in 2021

In 2021, Sonnet BioTherapeutics Holdings, Inc.'s disclosed short interest ran from 5.16% of shares outstanding on 15 Jan 2021 to 0.57% on 31 Dec 2021, a change of -4.59 percentage points. The year's high was 20.50% on 15 Sep 2021 and its low 0.57% on 31 Dec 2021, averaging 6.63% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.18 days on 13 Aug 2021. Full history: Sonnet BioTherapeutics Holdings, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Sonnet BioTherapeutics Holdings, Inc. in 2021

2021 in figures

Start of year
5.16% (15 Jan 2021)
End of year
0.57% (31 Dec 2021)
Change
-4.59 pp
High
20.50% (15 Sep 2021)
Low
0.57% (31 Dec 2021)
Average
6.63%
Highest days to cover
7.18 (13 Aug 2021)
SEC filings marked
8

Every report in 2021

Sonnet BioTherapeutics Holdings, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20215.16%1.48
29 Jan 20215.00%1.00
12 Feb 20214.26%1.00
26 Feb 20213.40%1.0010-Q filed, results (8-K)
15 Mar 20214.91%1.00
31 Mar 20212.24%1.00
15 Apr 20211.96%1.09
30 Apr 20211.71%1.00
14 May 20214.07%1.00
28 May 20212.48%1.0010-Q filed, results (8-K)
15 Jun 20213.59%1.00
30 Jun 20216.70%1.68
15 Jul 20219.96%2.86
30 Jul 202115.31%3.89
13 Aug 202113.33%7.18
31 Aug 202119.46%1.0010-Q filed, results (8-K)
15 Sep 202120.50%1.00
15 Dec 20211.38%1.00
31 Dec 20210.57%1.0010-K filed, results (8-K)

See also: Sonnet BioTherapeutics Holdings, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.